We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
TIRX | Tian Ruixiang Holdings Ltd | 1.14 | 0.65525 | 135.17% | 10,465,585 |
SMFL | Smart for Life Inc | 0.76 | 0.275 | 56.70% | 2,403,150 |
TRVN | Trevena Inc | 0.5295 | 0.1275 | 31.72% | 3,499,172 |
SECO | Secoo Holding Ltd | 0.46 | 0.0941 | 25.72% | 554,686 |
SINT | SiNtx Technologies Inc | 0.0446 | 0.0073 | 19.57% | 28,451,202 |
ALRN | Aileron Therapeutics Inc | 4.99 | 0.74 | 17.41% | 4,569 |
HOLO | MicroCloud Hologram Inc | 2.63 | 0.39 | 17.41% | 588,678 |
ELWS | Earlyworks Co Ltd | 0.70 | 0.1002 | 16.71% | 125,240 |
CNTB | Connect Biopharma Holdings Inc | 1.75 | 0.20 | 12.90% | 546 |
POAI | Predictive Oncology Inc | 1.45 | 0.1513 | 11.65% | 272 |
SDOT | Sadot Group Inc | 0.25 | 0.0256 | 11.41% | 2,610 |
RADNOR, Pa., April 17, 2024 /PRNewswire/ --Â NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The U.S. Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders, defined as one that affects fewer than 200,000 people in the U.S. In addition to providing a seven-year term of market exclusivity upon final FDA approval, orphan drug designation also positions Soligenix to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees for the potential submission of a Biologics License Application (BLA), and certain tax credits.
"The fourth quarter was the end of Sundry's bottom, which our first quarter results will reflect. Despite lower revenue contribution from Sundry in the fourth quarter, we almost achieved break even net income due to our cost savings (excluding non-cash expenses). Based on first quarter wholesale shipments and second quarter wholesale bookings, we are excited to see revenue growth meaningfully re-accelerate. This increase in the revenue trend will be coupled with a significantly lower operating expense structure," said Hil Davis, CEO of Digital Brands Group.
MENLO PARK, Calif., April 16, 2024 /PRNewswire/ -- Cyngn Inc. (the "Company" or "Cyngn") (Nasdaq: CYN) today announced the notice of allowance for a new patent, 17/812,072, for the Company's autonomous vehicle (AV) solutions. This patent covers the generation of a compensated environmental model by applying methods to address challenges that arise from using sensors that are in motion while collecting data and the inherent processing delay that exists between sensing and generating an environmental model.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 61,636.85 | -2,207.11 | -3.46% | 1.21T | 7,150,920,844 |
ETH | Ethereum | 3,006.21 | -78.61 | -2.55% | 361.52B | 3,060,912,000 |
USDT | Tether USD | 0.99994 | -0.00006 | -0.01% | 97.84B | 443,173,026 |
BNB | Binance Coin | 538.78 | 0.641588 | 0.12% | 84.93B | 467,946,618 |
SOL | Solana | 134.37 | -2.00 | -1.47% | 59.31B | 2,142,431,839 |
STETH | stETH | 3,001.28 | -62.99 | -2.06% | 29.32B | 16,345,765 |
USDC | USD Coin | 1.00 | 0.00 | 0.00% | 28.07B | 1,227,656,387 |
XRP | Ripple | 0.4974 | 0.0007 | 0.14% | 27.13B | 444,042,553 |
TONCOIN | Wrapped TON Coin | 6.15 | -0.199143 | -3.13% | 21.36B | 224,211,449 |
DOGE | Dogecoin | 0.14903 | -0.00702 | -4.50% | 21.27B | 639,490,361 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions